Antibody/siRNA Nanocarriers to Treat Metastatic Triple-Negative Breast Cancer

Technology

The treatment of triple-negative breast cancer (TNBC) faces significant challenges due to the aggressive nature of the disease and the absence of targeted therapies. TNBC does not express the common receptors targeted by current breast cancer treatments, and is prone to early recurrence and metastasis, highlighting the urgent need for innovative therapies.Researchers at the University of Delaware have developed a novel dual-delivery system of nanoparticles to combat TNBC.Engineered to co-deliver antagonistic antibodies and small interfering RNAs (siRNAs) directly to cancer cells, the nanoparticles target the Frizzled7 receptors abundantly expressed on TNBC cells. This effectively blocks the Wnt signaling pathways essential for cancer cell proliferation and metastasis. Simultaneously, the siRNAs suppress the gene expression of β-catenin, a key protein in the Wnt signaling cascade. This two-pronged attack inhibits tumor growth and spread and significantly reduces the likelihood of recurrence. By addressing the Wnt signaling pathway at both the receptor and post-receptor levels, this technology offers a promising new therapeutic option for managing a form of cancer that has historically been difficult to treat.

Benefits

  • Delivers antibodies and siRNAs within the same nanoparticle, ensuring simultaneous action that enhances treatment efficacy by attacking the cancer through multiple mechanisms.
  • Targets the Frizzled7 receptors overexpressed in TNBC cells, enabling precise nanoparticle delivery to cancer cells while minimizing impact on healthy cells and reducing side effects.
  • Effectively inhibits the Wnt signaling pathway, a key driver of TNBC growth and metastasis, by blocking initiating receptor interactions and suppressing downstream gene expression.
  • Overcomes drug resistance by targeting Wnt signaling at multiple levels, potentially reducing toxicity compared to conventional chemotherapy and enhancing efficacy against resistant TNBC forms.
  • Shows significant reductions in tumor growth, lung metastasis, and recurrence likelihood in preclinical models, indicating strong potential for improved patient outcomes in clinical settings.

Applications

  • Pharmaceutical Companies
  • Biotechnology Firms
  • Oncology-focusedCompanies
  • Clinical Research Organizations